DaVita vs Bio-Techne
DaVita (DVA), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bio-Techne is worth $11.4B on the stock market and DaVita $11B: Bio-Techne is valued at 4% more. DaVita trades at 13.2 times earnings and Bio-Techne at 66.8; operating margins in their latest fiscal years were 15.0% and 20.7%. Over the past year DaVita's share price has moved +49.5% and Bio-Techne's +25.2%.
Key facts
- DaVita market value
- $11B
- Bio-Techne market value
- $11.4B
- DaVita P/E
- 13.2
- Bio-Techne P/E
- 66.8
- DaVita revenue
- $13.6BFY to 2025-12-31
- Bio-Techne revenue
- $1.2BFY to 2026-06-30
- Superinvestors holding both
- 0
Market values as of .
| Measure | DaVita | Bio-Techne |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-06-30 |
| Size | ||
| Market cap | $11Blower | $11.4Bhigher |
| Revenue | $13.6Bhigher | $1.2Blower |
| Earnings | $746.8Mhigher | $181.9Mlower |
| Employees | 78,000higher | 3,000lower |
| Total assets | $17.5Bhigher | $2.6Blower |
| Valuation | ||
| P/E | 13.2lower | 66.8higher |
| P/S | 0.8lower | 9.4higher |
| P/B | — | 5.3 |
| Dividend yield | 0.00%lower | 0.33%higher |
| Profitability | ||
| Operating margin | 15.0%lower | 20.7%higher |
| Balance sheet | ||
| Net assets | -$651.1Mlower | $2.1Bhigher |
| Total liabilities | $16.3Bhigher | $478.5Mlower |
| Total debt | $10.3Bhigher | $200Mlower |
| Cash on hand | $676.4Mhigher | $264.7Mlower |
| Price change | ||
| Today | +0.25%higher | 0.00%lower |
| 1 year | +49.5%higher | +25.2%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
DaVita only (2)
- Warren Buffett2.1%
- Josef Lakonishok0.3%
Bio-Techne only (7)
- Sequoia Fund team3.9%
- Wallace Weitz1.3%
- Lee Ainslie1.0%
- Mairs & Power team0.8%
- Henry Ellenbogen0.3%
- Paul Tudor Jones0.3%
- Larry Robbins0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns DVA · Who owns TECH
More on DaVita
Further comparisons
DaVita against its closest peers
Bio-Techne against its closest peers
Learn
Questions and answers
Which is bigger, DaVita or Bio-Techne?
By market value, Bio-Techne is the larger: $11.4B against $11B for DaVita. By revenue in its latest fiscal year, DaVita is the larger: $13.6B against $1.2B for Bio-Techne.
Which has the higher P/E ratio?
Bio-Techne: 66.8, against 13.2 for DaVita. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Bio-Techne: 20.7%, against 15.0% for DaVita. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Bio-Techne: 0.33%, against 0.00% for DaVita. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
DaVita: $10.3B, against $200M for Bio-Techne. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both DaVita and Bio-Techne?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold DaVita and 7 hold Bio-Techne.
Cite this page
Funkfolio, “DaVita vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/dva-vs-tech
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.